CHEK2 and cancer: Furthermore, Zoppoli et al. [54] studied a panel of 60 established cancer cell lines showing that the high heterogeneity of CHEK2 expression in cancer cells is primarily due to its inactivation (low gene expression, alternative splicing, point mutations, copy-number alterations, or premature truncation) or reduction of protein levels.